GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (NYSE:TARO) » Definitions » ROA %
中文

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) ROA %

: 3.77% (As of Dec. 2023)
View and export this data going back to 1987. Start your Free Trial

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Taro Pharmaceutical Industries's annualized Net Income for the quarter that ended in Dec. 2023 was $80.8 Mil. Taro Pharmaceutical Industries's average Total Assets over the quarter that ended in Dec. 2023 was $2,141.3 Mil. Therefore, Taro Pharmaceutical Industries's annualized ROA % for the quarter that ended in Dec. 2023 was 3.77%.

The historical rank and industry rank for Taro Pharmaceutical Industries's ROA % or its related term are showing as below:

TARO' s ROA % Range Over the Past 10 Years
Min: -16.29   Med: 11.63   Max: 32.05
Current: 2.14

During the past 13 years, Taro Pharmaceutical Industries's highest ROA % was 32.05%. The lowest was -16.29%. And the median was 11.63%.

TARO's ROA % is ranked better than
51.66% of 1082 companies
in the Drug Manufacturers industry
Industry Median: 1.735 vs TARO: 2.14

Taro Pharmaceutical Industries ROA % Historical Data

The historical data trend for Taro Pharmaceutical Industries's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taro Pharmaceutical Industries Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.34 10.91 -16.29 2.54 1.18

Taro Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.38 1.29 1.88 1.61 3.77

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Taro Pharmaceutical Industries's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taro Pharmaceutical Industries ROA % Distribution

For the Drug Manufacturers industry and Healthcare sector, Taro Pharmaceutical Industries's ROA % distribution charts can be found below:

* The bar in red indicates where Taro Pharmaceutical Industries's ROA % falls into.



Taro Pharmaceutical Industries ROA % Calculation

Taro Pharmaceutical Industries's annualized ROA % for the fiscal year that ended in Mar. 2023 is calculated as:

ROA %=Net Income (A: Mar. 2023 )/( (Total Assets (A: Mar. 2022 )+Total Assets (A: Mar. 2023 ))/ count )
=25.445/( (2176.362+2135.513)/ 2 )
=25.445/2155.9375
=1.18 %

Taro Pharmaceutical Industries's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=80.832/( (2119.473+2163.179)/ 2 )
=80.832/2141.326
=3.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Taro Pharmaceutical Industries  (NYSE:TARO) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=80.832/2141.326
=(Net Income / Revenue)*(Revenue / Total Assets)
=(80.832 / 628.58)*(628.58 / 2141.326)
=Net Margin %*Asset Turnover
=12.86 %*0.2935
=3.77 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Taro Pharmaceutical Industries ROA % Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description

Traded in Other Exchanges
Address
14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.
Executives
Sun Pharma Global Inc 10 percent owner
Sun Pharmaceutical Industries Ltd 10 percent owner, other: Affiliated Party 17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST) K7 400 093
Alkaloida Chemical Co Exclusive Group Ltd. 10 percent owner KABAY JANOS UT 29., TISZAVASVARI K5 4440
Franklin Resources Inc 10 percent owner FRANKLIN RESOURCES INC, ONE FRANKLIN PARKWAY, SAN MATEO CA 94403

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Headlines

From GuruFocus

Taro Achieves Global Resolution of DOJ Antitrust Investigations

By Business Wire Business Wire 07-24-2020

Taro to Announce Full Year Results on May 26, 2022

By Business Wire Business Wire 05-21-2022

Taro to Release Full Year Results on May 23, 2023

By Business Wire Business Wire 05-18-2023

Taro to Announce Third Quarter Results on January 27, 2021

By Business Wire Business Wire 01-21-2021

Taro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S.

By Business Wire Business Wire 09-28-2020

Taro to Acquire Alchemee From Galderma

By Business Wire Business Wire 02-22-2022